Metrics as of 10/16/2026, 05:54 PM (Berlin time), refresh in progress.
Foghorn Therapeutics Stock
Foghorn Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Adrian H. Gottschalk
- Employees
- 106
- Market cap
- $111 M
- IPO
- 23/10/2020
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate,…
Foghorn Therapeutics stock: price history
1D
-0.8%
1W
-6.3%
1M
-55.0%
6M
-64.6%
YTD
-65.3%
1Y
-56.5%
2Y
-76.9%
5Y
-84.9%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~4% stronger price swings than usual
Ask the agents about Foghorn Therapeutics
Analyst assessment of Foghorn Therapeutics
PRICE TARGET LOW
US$2.00
CONSENSUS
US$4.00
MEDIAN
US$5.00
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
8
BUY
4
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 02/10/2026
Foghorn Therapeutics stock metrics
P/E
-1.89
P/B
-1.63
EV/EBITDA
-1.38
RETURN ON EQUITY
8.9%
NET MARGIN
-44.7%
DEBT/EQUITY
-0.53
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
43.1%
FLOAT SHARES
25,576,661
AVG. DAILY VOLUME (30D)
1,052,968
Institutional holders
Comparable stocks
Frequently asked questions about Foghorn Therapeutics stock
What does Foghorn Therapeutics do?
Foghorn Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Adrian H. Gottschalk, the company employs around 106 people.
The IPO was on 23/10/2020; the stock trades on NASDAQ under the ticker FHTX.
What do analysts say about Foghorn Therapeutics stock?
12 analysts rate the stock, the consensus is Buy (as of 02/10/2026).
The average price target is US$4.00, ranging from US$2.00 to US$5.00, with a median of US$5.00.
This is an external assessment, not a statement by Market Jury.
When does Foghorn Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 4% stronger than usual.
Does Foghorn Therapeutics pay a dividend?
No, Foghorn Therapeutics currently does not pay a dividend.
Which stocks are comparable to Foghorn Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Foghorn Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Foghorn Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.